Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.332
−$0.069 · -17.21%
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Previous close
$0.332
−$0.069 · -17.21%
After-hours
$0.3497
+$0.0177 · +5.33%
Sep 10, 7:59 PM ET
Regular session · ET · Market data may be delayed.
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Day range
Current $0.332
52-week range
Current $0.332
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
55
Mixed
Risk
77
High Risk
Momentum
24
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Day range
Current $0.332
52-week range
Current $0.332
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | — | 89K USD | — |
| Gross profit | — | — | — | −89K USD | — |
| Research and development | 6.23M USD | 5.7M USD | 7.27M USD | 6.42M USD | 3.08M USD |
| Selling, general, and administrative | 4.86M USD | 4.2M USD | 4.78M USD | 7.05M USD | 2.51M USD |
| Operating expenses | 11.09M USD | 9.9M USD | 12.05M USD | 13.46M USD | 5.59M USD |
| Interest income | 13K USD | 2K USD | 178K USD | 91K USD | — |
| Interest expense | — | 311K USD | 550K USD | 15K USD | 1.15M USD |
| Depreciation and amortization | 16K USD | 22K USD | 21K USD | 89K USD | 3K USD |
| Operating income | −11.09M USD | −9.9M USD | −12.05M USD | −13.55M USD | −5.59M USD |
| Net income | −11.13M USD | −10.21M USD | −10.11M USD | −12.34M USD | −4.04M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
